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Objective: This study aimed to ascertain the relationship between early diagnosis of giant-
cell tumors (GCT) and their prognosis, by correlating the time of symptom onset with the
staging of the injury (through the Campanacci classiﬁcation at the time of diagnosis), and
with  the type of treatment. The secondary objective of the study was to outline the epi-
demiological proﬁle of patients with GCT in the region where the data were gathered, and
to  compare them with data in the literature.
Methods: The authors present an evaluation on 61 patients diagnosed with bone GCT, with
regard to the site of involvement, age, initial symptoms, time of symptom onset, classi-
ﬁcation and type of treatment, among patients attended between May 1994 and August
2009.
Results: The threshold indicated as the limit for Campanacci stage I tumors to be the com-
monest diagnosis, with a 98.2% chance that the treatment would be non-aggressive, was
2  months after symptom onset. This ﬁnding was statistically signiﬁcant (p = 0.017). Every
additional month increased the chance that a patient would be diagnosed with an advanced-
stage tumor by 10.94%, in relation to the chances of having the other two stages of the
tumor.
Conclusion: The study result not only suggests that the alternative hypothesis that the earlier
the  diagnosis of GCT is, the less severe the lesion will be, has been conﬁrmed; but also espe-
cially predicts the relationship between the time of symptom appearance and the severity
of  the tumor.
© 2015 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda. All rights reserved. Work performed in the Hospital do Câncer de Pernambuco, Recife, PE, Brazil.
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Tumor  de  células  gigantes:  análise  sobre  importância  do  diagnóstico
precoce  e  perﬁl  epidemiológico
Palavras-chave:
Tumores de células
gigantes/diagnóstico
Tumores de células
gigantes/epidemiologia
Tumores de células
gigantes/terapia
r  e  s  u  m  o
Objetivo: Presumir a relac¸ão entre o diagnóstico precoce do tumor de células gigantes (TCG)
e  o seu prognóstico, relacionar o tempo de surgimento dos sintomas com o estadiamento da
lesão, por meio da classiﬁcac¸ão de Campanacci no momento do diagnóstico, e com tipo de
tratamento. O objetivo secundário do estudo é trac¸ar o perﬁl epidemiológico dos pacientes
com TCG da região onde foram colhidos os dados e compará-lo com dados da literatura.
Métodos: Avaliac¸ão de 61 pacientes diagnosticados com tumor de células gigantes ósseo
quanto ao local de acometimento, idade, sintomatologia inicial, tempo do surgimento dos
sintomas, classiﬁcac¸ão e tipo de tratamento em pacientes atendidos entre maio de 1994 e
agosto de 2009.
Resultado: Aponta o marco de dois meses após o início da sintomatologia como data limite,
quando seria mais comum o diagnóstico de tumor estágio I de Campanacci e com 98,2% de
chance de ser tratado de modo não agressivo, dados com relevância estatística (p = 0,017). A
cada  aumento de um mês a chance de um paciente ser diagnosticado com tumor em estágio
avanc¸ado é 10,94% maior do que em relac¸ão aos outros dois estágios do tumor.
Conclusão: O resultado do estudo sugere não somente a conﬁrmac¸ão da hipótese opcional de
que quanto mais precoce o diagnóstico de TCG, menos grave é a lesão, mas, principalmente,
prediz a relac¸ão do tempo de surgimento do sintoma com a gravidade do tumor.
©  2015 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier
Editora Ltda. Todos os direitos reservados.
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would be capable of allowing the assumption of low sever-ntroduction
one giant-cell tumors (GCTs) are benign mesenchymal
eoplasms with aggressive characteristics. Histologically, it
s known that GCTs were ﬁrst described by Cooper apud
cCarthy1 and were considered to be “fungal medullary exos-
oses”. In 1845, Lebert et al. apud McCarthy1 described a group
f bone tumors with giant multinucleated cells that presented
 tendency to recur, but which could be cured through ampu-
ation. Histopathological evaluations on GCTs reveal that they
re formed by vascularized tissue consisting of stroma of
usiform or ovoid cells and by the presence of numerous mul-
inucleated giant cells that resemble osteoclasts. They present
haracteristics common to many  different tumoral and pseu-
otumoral lesions, and analysis together with the clinical and
maging characteristics is needed in order to conﬁrm the diag-
osis.
According to a series at the Mayo Clinic,2 these tumors
ccount for 5% of bone neoplasms and are slightly more  preva-
ent in females. The age group most affected is between the
econd and fourth decades of life. GCTs generally affect a sin-
le bone. The commonest sites affected are the distal femur,
roximal tibia and distal radius.
The clinical condition consists of progressive pain and
ncreased joint volume, which may be associated with
oint symptoms such as mechanical blocking and synovi-
is. These symptoms are often initially related to physical
ctivity and the pain only rarely becomes incapacitating.
 diagnosis of GCT is suspected when, in addition to the
bovementioned clinical condition, radiographic evaluationreveals a tumor of osteolytic appearance that destroys the
entire epiphysis and may reach as far as the joint cartilage
(characteristics of aggressiveness in the radiological evalua-
tion). The diagnosis is conﬁrmed through histopathological
analysis.
In 1990, Campanacci et al.3 presented a radiographic clas-
siﬁcation for GCTs that describes three different grades: stage
1 – small, quiescent and intraosseous lesions; stage 2 – active
or aggressive tumors, with compromised bone cortex, but pre-
senting intact periosteum; stage 3 – aggressive, with invasion
of adjacent soft issues.
Historically, the treatment consisted of simple curettage,
but this method was shown to give rise to a high recur-
rence rate. Currently, the techniques most used are curettage
with adjuvant therapy, resection of the affected segment with
fusion-like reconstruction or auto/homograft replacement or
use of endoprostheses.
Nonspeciﬁc initial symptoms, lack of medical training
directed toward primary care and difﬁculty in accessing refer-
ral hospitals makes it harder to achieve early diagnosis and
adequate treatment for GCTs. The present study had the aims
of evaluating the relationship between early diagnosis of GCT
and its prognosis and correlating the length of time since
symptoms appeared with the staging of the lesion, by means
of the Campanacci classiﬁcation at the time of diagnosis, and
with the type of treatment. This study also had the aim of
establishing time markers for early diagnosis of GCT thatity of the lesion, with the need for less aggressive types of
treatment, and serving as a guide for public policies for diag-
nosing and providing early treatment for GCT.
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Table 1 – Comparison of mean ages and lengths of
follow-up in relation to tumor stage.
Tumor stage (mean ± SD) p-value
I II III
Age (years) 38.3 ± 13.7 29.5 ± 10.6 34.1 ± 13.9 0.311
Time (months) 1.5 ± 0.5 6.4 ± 0.8 10.4 ± 2.1 0.017a
in the ﬁfth month, this probability would be 13.7%. If this
same patient were to be diagnosed only after 12 months, this
probability would be 81.5%.
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Material  and  method
In September 2014, a cross-sectional descriptive study
was conducted among patients at the Cancer Hospital of
Pernambuco. All the medical ﬁles of patients who had been
diagnosed with GCT between May 1994 and August 2009 were
reviewed. Patients with soft-tissue GCT; patients hospitalized
due to tumor recurrence; cases in which the time that had
elapsed between the onset of symptoms and the diagnosis
records was not mentioned; and records with conﬂicting or
incomplete data, i.e. absence of histopathological conﬁrma-
tion, illegible information, incomplete admission forms and
non-explanatory surgical descriptions, were excluded from
the data-gathering.
Through excluding the groups cited above from the data-
gathering, 61 patients were selected. These cases had medical
ﬁles that had been ﬁlled out legibly, with the abovementioned
information complete and non-conﬂicting. The following
information was sought in these medical ﬁles: time elapsed
between the onset of symptoms and the tumor diagnosis
at the referral oncological hospital; site of tumor involve-
ment; patient’s age; patient’s place of origin; type of treatment
implemented; Campanacci classiﬁcation on admission; and
symptoms presented during the attendance. The process of
clinical investigation, lesion classiﬁcation and treatment was
implemented by qualiﬁed professionals who were members
of the Brazilian Society of Oncological Orthopedics.
The sample was classiﬁed in accordance with the Cam-
panacci system and was divided into two  groups relating to
the treatment required. The patients with GCTs that could
be resected through curettage with adjuvant therapy were
grouped as “non-advanced” cases, while those who required
interventions that were more  “aggressive” were considered to
be “advanced” cases.
This study was submitted to the ethics committee of the
healthcare institution indicated through the Brazil platform,
for authorization.
Statistical  analysis
The results from the quantitative variables were expressed as
means and standard deviations, while the results from the
qualitative variables were expressed as absolute and relative
frequencies. The Kruskal–Wallis test was used to ascertain
possible differences in mean time taken for treatment and in
patient age, in relation to tumor stage. A logistic regression
model was used to correlate the time taken for treatment and
the tumor stage.
Results
The mean age among the patients with a tumor in Campanacci
stage I was 38.3 ± 13.7 years, while those in stage II presented
a mean of 29.5 ± 10.6 years. Patients with a stage III tumor pre-
sented a mean of 34.1 ± 13.9 years. It was seen that there was
no statistically signiﬁcant difference in mean age in relation
to tumor stage (p = 0.311) (Table 1).a Statistically signiﬁcant.
The patients with stage I tumors presented a mean time
taken until the diagnosis of 1.5 ± 0.5 months. Those with stage
II tumors presented a mean of 6.4 ± 0.8 months and those with
stage III tumors, 10.4 ± 2.1 months. It was observed that there
were signiﬁcant differences in the time taken until the diag-
nosis, in relation to the tumor stage (p = 0.017), i.e. patients
at the initial stage presented shorter times taken to make the
diagnosis than those at advanced stages of the tumor (Table 1).
It was seen that patients in stage I presented shorter times
to make the diagnosis than those in stages II and III: p <0.0001
and <0.0001, respectively (Fig. 1).
It was seen that the time taken to make the diagnosis for
patients with stage III tumors was longer than the time for
patients with stage II: p = 0.013 (Fig. 1).
Through logistic regression analysis (Eq. (1)), it was
observed that for every 1-month increase, the chance that
a patient would be diagnosed with a tumor at the advanced
stage was 10.94% greater than at the other two tumor stages.
log(− log(1 − ˘(x))) = −1.64 + 0.1 tempo (1)
where ˘(x) is the probability that a patient would be classiﬁed
as having an advanced stage of the tumor.
It was seen from Table 2 that patients with a time of 1
month taken to make the diagnosis presented a probability
of 0.5% of being classiﬁed as having an advance stage of the
tumor, while if this same patient were to be diagnosed onlyTumor stage
Fig. 1 – Boxplot of the time taken to make a diagnosis for
the patients, in relation to tumor stage.
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Table 2 – Probability of tumor stage classiﬁcation, in
relation to the length of follow-up.
Probability of
classiﬁcation
Length of follow-up (months)
1 2 5 8 10 12
Advanced 0.5 1.8 13.7 48.2 63.3 81.5
Non-advanced 99.5 98.2 86.3 51.8 36.7 18.5
Length of follow-up
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Table 4 – Incidence of GCT according to location in
skeleton.
Site of involvement No. of patients Percentage
Distal femur 20 32.78%
Proximal 7 11.47%
Distal tibia 6 9.83%
Distal radius 6 9.83%tage, in relation to the time taken to make the diagnosis.
It was seen in Fig. 2 that approximately 20% of the patients
ere classiﬁed was presenting an advanced stage of the tumor
n the sixth month. In the eighth month of the follow-up,
pproximately 50% of the patients presented tumors at an
dvance stage, while 80% of the patients were classiﬁed as
resenting an advanced stage of the disease around the 11th
onth.
Table 3 presents the prevalences of symptoms among the
atients studied. It shows that pain alone was the commonest
ymptom and tumor formation was the commonest clinical
ign.
The incidence of GCTs according to their location in the
keleton is presented in Table 4, which shows that they affect
he epiphyses of long bones, most commonly at the knee. In
Table 3 – Prevalence of symptoms.
Symptoms N %
Pain 28 46.7
Tumor formation 17 28.3
Pain and tumor formation 4 6.7
Increased volume 4 6.7
Pain and increased volume 2 3.3
Pathological fracture 2 3.3
Pain and pathological fracture 2 3.3
Edema and pain 1 1.7Phalanges 5 8.19%
Others 17 27.86%
addition to these regions, GCTs have also been found in the
calcaneus, proximal humerus, ulna, hop and proximal radius.
Discussion
The results from this study suggest not only that it has pro-
vided conﬁrmation of the optional hypothesis that the earlier
the diagnosis of GCT is made, the lower the severity of the
lesion will be, but also especially, that this predicts the rela-
tionship between the time of symptom onset and the severity
of the tumor. For example, in patients who are diagnosed 1
month after symptoms ﬁrst appear, their chance of presenting
a lesion that can be treated through curettage plus adjuvant
treatment 99.5%, which has beneﬁts both for the patient and
for the public healthcare system, in comparison with surgical
procedures that are more  aggressive.
GCTs were found in our series of 61 patients mostly
between their third and fourth decades of life, and this ﬁnding
is in line with the data in the literature.3–5 Unlike a study6 in
which 31% of the patients were diagnosed with pathological
fractures, we  found in our series that only 3.3% of our patients
had such lesions.
The observation that only one patient in our study pre-
sented metastasis (1.6%) is concordant with the worldwide
literature,2,7 in which it has been estimated that the risk of
metastasis from GCT is between 1 and 3%. According to Renard
et al.,8 the explanation for the metastatic foci lies in the fact
that tumor cells may be found in peripheral vessels of the bone
site affected.
Comparing the incidence of GCTs regarding their location
in the skeleton with what was demonstrated by Jesus-Garcia
et al.,6 we obtained similar data, as can be seen in Table 4. The
knee is the location of highest incidence and accounts for 44%
of the cases.
With  the aim of establishing time markers for early diag-
nosis in cases of GCT, the objective that was taken on was
to identify lesions classiﬁed as Campanacci stage I or II that
it would be possible to treat through curettage plus adjuvant
therapy, which were grouped as non-advanced cases in the
statistical analysis of this study. The results showed that a
time marker of 2 months after the onset of symptoms was the
time limit for the period in which the commonest diagnosis
would be a Campanacci stage I tumor, with a 98.2% chance of
being capable of non-aggressive treatment. This ﬁnding was
statistically signiﬁcant (p = 0.017).In order to reach the time marker demonstrated in this
study, improvements in public healthcare policies will be
needed. Investment in human and structural resources within
primary care, capacitation of healthcare professionals and
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regularization of rapid passage between primary care and spe-
cialist units for oncological treatment are ways of making the
public healthcare system capable of timely diagnosis for GCT
cases.
The present study found that there was high prevalence
of generic signs and symptoms, which caused difﬁculty
regarding clinical suspicion and early diagnosis. The presence
of joint pain and/or tumor formation was shown to be a sign
of suspicion for investigating possible GCTs.
From analysis on the result obtained regarding mean age
in relation to lesion severity at the time of diagnosis, it was
concluded that there was no statistical signiﬁcance. Thus,
symptoms that are highly prevalent among older patients,
such as joint pain, need to be better investigated. Likewise, in
attending younger patients, tumor etiology needs to be noted,
given that the data obtained in several studies have demon-
strated its importance for early diagnosis.
Conclusion
This study demonstrated that the mark of 2 months after
symptom onset was the time limit for the period in which a
diagnosis of Campanacci stage I tumors would be more com-
mon, with a 98.2% chance of only needing non-aggressive
treatment. This ﬁnding was statistically signiﬁcant (p = 0.017).
With every 1-month increase, the chance that a patient would
be diagnosed with a tumor at an advanced stage is 10.94%
greater than in relation to the other two tumor stages. The
epidemiological proﬁle of patients with GCT in this region is
8 1 6;5  1(1):58–62
concordant with the data in the worldwide literature, with
regard to age, risk of metastasis and site affected.
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